甲胺诱导的眼肌化学
Marya Ahsan1, Deba Jalal Nizami2
1Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia.
Indian journal of pharmacology
|December 17, 2024
概括
梅特福林用于PCOS可能会通过损害维生素B12吸收而导致眼肌化学. 停止服用甲福明可以缓解抽,这凸显了需要监测服用这种药物的患者B12水平的必要性.
科学领域:
- 内分泌学 在内分泌学.
- 神经学 神经学
- 眼科医生 眼科 眼科
背景情况:
- 甲胺是一种常见的治疗多囊性卵巢综合征 (PCOS),特别是在肥胖妇女,帮助减肥和月经周期调节.
- 甲胺的潜在副作用是维生素B12吸收受损,尽管对神经症状的临床意义尚未完全确定.
- 眼肌化症,以眼抽为特征,通常是良性的,但可能是令人痛苦的,并影响生活质量.
研究的目的:
- 在患有PCOS的患者中报告可能与甲福林治疗相关的眼肌化病病例.
- 调查维生素B12缺乏作为这种不良影响的机制的作用.
- 强调在接受甲胺治疗的患者中监测维生素B12水平的重要性.
主要方法:
- 一个病例报告,一名39岁的女性患有PCOS,接受了甲福林治疗.
- 临床观察眼肌化学症状,对保守治疗的反应,口服甲基可巴胺和美特福林的停止/重新引入.
- 评估维生素B12水平,并排除其他潜在的混因素 (压力,睡眠不足,咖啡因).
主要成果:
- 患者出现了令人痛苦的单侧眼抽,对初始治疗没有反应.
- 检测到了极低的维生素B12水平.
- 眼肌化症的症状在停止服用甲福林后消失,并在重新服用甲福林后复发.
结论:
- 甲胺诱导的维生素B12吸收不良可能会引发敏感个体的眼肌化学.
- 眼肌化,虽然往往是自我限制的,但可以是药物诱导和影响患者的福祉.
- 建议对长期接受甲福林治疗的患者进行维生素B12水平的常规监测,以防止不良影响.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
01:06Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
01:28Disorders of the Skeletal Muscle
871
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
871
01:15Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
01:23Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K